TNXP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
TNXP is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock has some bullish fundamental headlines and insider buying, but the current technical setup is weak, the options market is cautious, and there is no clear Intellectia buy signal today. I would not treat this as an immediate long-term entry at the current price of 12.44.
The trend is still bearish. MACD histogram is negative and worsening, RSI_6 at 37.50 shows weak momentum without being oversold, and the moving averages are aligned bearishly with SMA_200 > SMA_20 > SMA_5. Price is below the pivot at 13.799 and only slightly above S1 at 12.325, which suggests the stock is trading near a short-term support area but has not yet reversed trend. The near-term pattern estimate suggests possible upside, but the broader technical structure still favors caution.
["TD Cowen initiated coverage with a Buy rating and a $22 price target.", "Analyst thesis highlights Tonmya's potential in fibromyalgia, a large underserved market.", "Tonix reported real-world efficacy data that appears positive for pain and sleep.", "Tonix's TNX-4800 adds a potential catalyst in Lyme disease prophylaxis.", "Insiders are buying, with buying amount up 1801.93% over the last month."]
["The stock is in a weak technical trend with bearish moving averages and negative MACD momentum.", "Options traders are leaning cautious, with put-call ratios above 1.", "Hedge funds are neutral, and there are no significant institutional trading trends.", "No recent congress trading data is available.", "The company has very high implied volatility, which often reflects uncertainty and speculative trading."]
No usable latest-quarter financial snapshot was provided because the financial data returned an error. Based on the available information, there is no confirmed quarterly revenue or earnings growth to support a long-term fundamental buy decision. The most recent business-related update is around the 2025 launch of TONMYA for fibromyalgia, but without quarter financials, growth quality cannot be verified.
Wall Street view is constructive but still early. TD Cowen initiated coverage on 2026-05-04 with a Buy rating and a $22 price target, citing Tonmya's promise in fibromyalgia and pipeline optionality in Lyme disease prophylaxis. Pros: clear upside target, large underserved market, and positive early efficacy commentary. Cons: the rating is only one initiation, and it is not yet supported by strong technical strength or broad institutional accumulation.
